BESREMi targets the bone marrow, the source of PV, so you can address the underlying disease1

Download the PharmaEssentia SOURCE Enrollment Form

PharmaEssentia SOURCE provides patients prescribed BESREMi with product support, insurance education, and access assistance.

PV, polycythemia vera; NCCN, National Comprehensive Cancer Network.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 5, 2022. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Besremi. Package insert. PharmaEssentia Corporation; 2021.